Potent neutralizing human monoclonal antibodies protect from Rift Valley fever encephalitis is a research paper published in JCI Insight (2024). On theSindex it has a DataRank of 0.292. It has been cited 6 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.292
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: R01 NS101100,R56 AI171920,R01 AI178378
NIAID NIH HHS
Grant: R01 AI150792
NIAID NIH HHS
Grant: R01 AI169850
NIAID NIH HHS
Grant: R01 AI178378
NINDS NIH HHS
Grant: R01 NS101100
NIAID NIH HHS
Grant: R56 AI171920
NIAID NIH HHS
Grant: UC7 AI180311
National Institutes of Health
Grant: 1R56AI171920-01
Comparative Analysis of Bunyavirus Neuropathogenesis
National Institutes of Health
Grant: 1R01NS101100-01A1
Neuroprotective anti-inflammatory drugs as a novel combination therapy for neurological Rift Valley Fever
National Institutes of Health
Grant: 1R01AI178378-01
Mechanisms of Neuronal Infection by Prototype Emerging Bunyaviruses
FWCI
2.04
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords